Migraine - FOI Response Register

FoI Number
2025-178
Subject
Migraine
Date Received
10/06/2025
Request and Response
  1. How many patients have been treated with the following drugs in the past 4 months?

 

•           Atogepant (Aquipta) – any disease

 - Nil

•           Erenumab (Aimovig) - any disease

 - 4

•           Eptinezumab (Vyepti) – any disease

 - Nil

•           Fremanezumab (Ajovy) - any disease

 - 3

•           Galcanezumab (Emgality) - any disease

 - Nil

•           Rimegepant (Vydura) – any disease

 - Nil

•           Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY –

In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested. NHS Shetland does not hold condition linked prescribing data

  1. How many patients have you treated in the last 4 months for acute migraine with:

•           Rimegepant (Vydura)

In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested. NHS Shetland does not hold condition linked prescribing data.

  1. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria?

NHS Grampian initiate treatments breaks for patients residing in Shetland.